+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 183 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are investigating treatments for hormone receptor-positive and HER2-negative breast cancer that is either locally advanced and cannot be removed by surgery or has spread to other body parts. The study focuses on comparing patritumab deruxtecan with chemotherapy or trastuzumab deruxtecan to see if patients live longer or have delayed cancer progression. This phase 3 trial evaluates these treatments in people who have had prior progression on CDK46 inhibitor plus endocrine therapy. Participants receive either patritumab deruxtecan through intravenous infusion every three weeks for about 13 months or treatment chosen by their doctor, which may include various chemotherapy drugs or trastuzumab deruxtecan up to 13 months. Treatments are given in cycles with specific dosing schedules depending on the drug selected. Rescue medications are also allowed as needed following approved guidelines. During the study, participants undergo regular assessments including scans to measure disease progression and evaluations of quality of life using standardized questionnaires. Researchers monitor overall survival and progression-free survival for up to 85 months. Safety is closely followed by recording adverse events and treatment discontinuations. The trial aims to provide detailed data on how these treatments affect patients over time and their impact on symptoms and functioning.

Age: 18Years +All GendersPhase 3
206 locations
S

Actively Recruiting

Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.

Age: 18Years +All GendersPhase 3
331 locations
E

Actively Recruiting

Researchers are evaluating the safety, optimal dose, and effectiveness of a combination treatment involving BNT323 trastuzumab pamirtecan and BNT327 pumitamig in people with advanced breast cancer. This includes patients with hormone receptor-positive or negative, HER2-positive, HER2-low, HER2-ultralow, HER2-null breast cancer, or triple-negative breast cancer. The study is a Phase III, multi-site, open-label trial designed to find the best dose and assess the treatments effects in these groups. The study has two parts. Part 1 involves dose escalation where participants with chemotherapy-pretreated advanced breast cancer receive various dose levels of BNT323 plus BNT327 to determine the recommended Phase 2 dose. Part 2 includes dose optimization and exploratory groups, beginning after Part 1s completion. In Part 2 Cohort 1, participants are randomized into four arms to receive either the combination at the recommended dose, the combination at another dose, BNT323 alone, or BNT327 alone. Other cohorts receive the recommended dose without randomization. Participants will undergo treatment cycles with intravenous infusions of the study drugs and be monitored for safety, side effects, and tumor response for up to 36 months. Assessments include tracking dose-limiting toxicities, adverse events, tumor scans, and response rates. Safety monitoring continues up to 90 days after the last dose. The study aims to provide detailed information on the best dose, safety, and potential benefits of these treatments for advanced breast cancer.

Age: 18Years +All GendersPhase 1Phase 2
81 locations
P

Actively Recruiting

Researchers are evaluating AV-380, an immunoglobulin G1 monoclonal antibody designed to bind human growth differentiation factor 15 GDF-15, a cytokine involved in cancer-induced cachexia. This phase 1B open-label dose escalation study aims to assess the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of AV-380 in cancer patients who have cachexia and elevated GDF-15 levels. Participants have metastatic solid tumors and are actively receiving standard of care chemotherapy. Participants receive AV-380 through intravenous infusion in ascending dose cohorts alongside their standard chemotherapy treatments. The study includes a dose escalation phase where the safety and appropriate dosage of AV-380 are evaluated. This phase allows researchers to monitor the effects of increasing doses of AV-380 over a study period of up to 4 months while patients continue their usual cancer therapies. During the study, participants will undergo assessments including monitoring for adverse events, toxicity, and laboratory abnormalities from enrollment until about 60 days after the last dose. Pharmacokinetic measures such as maximum concentration Cmax, time to maximum concentration Tmax, and area under the curve AUC will also be evaluated. The total involvement includes regular evaluations to track safety, drug behavior in the body, and immune responses to AV-380.

Age: 18Years +All GendersPhase 1
12 locations
O

Actively Recruiting

Healthy Volunteer

Researchers are evaluating how cannabis use affects the quality of life in patients with multiple myeloma who are receiving chemotherapy. This observational study compares patients who use cannabis with those who do not, aiming to understand both potential benefits and harms. It uses specific tools like the Functional Assessment of Cancer Therapy-Multiple Myeloma FACT-MM and patient-reported symptoms to assess these effects over time. Participants are divided into two groups one group completes surveys and provides blood samples throughout the study, and the other group consists of healthcare providers who complete a survey related to the study. The study follows participants for up to one year, focusing on longitudinal patterns in quality of life and the potential therapeutic benefits and adverse effects associated with cannabis use. During the study, patients complete questionnaires and provide blood samples regularly. Researchers monitor their symptoms and any side effects using standardized scales such as the Edmonton Symptoms Assessment Scale and Common Terminology Criteria for Adverse Events. The study tracks changes over time to better understand how cannabis use interacts with cancer-directed treatments and overall patient well-being.

Age: 18Years +All Genders
11 locations
V

Actively Recruiting

Researchers are exploring a new multiplex ELISA assay to improve the non-invasive detection of bladder cancer BCa in patients who have microscopic hematuria, a common sign of BCa. This study aims to validate this diagnostic test, which targets a BCa-associated signature in urine samples, to overcome limitations of existing urine-based tests that miss many early or low-grade cancers. Detecting BCa early is crucial since current methods often require invasive bladder examinations. The study involves collecting voided urine samples from patients with microscopic hematuria and analyzing them using the multiplex ELISA assay. The performance of this assay will be compared to standard diagnostic procedures, including cystoscopy, which involves inserting a camera into the bladder, and other urine tests like VUC and NMP-22 BladderChek. This comparison will help confirm the sensitivity and specificity of the new assay within one year. Participants will provide urine samples and undergo cystoscopy and upper tract imaging as part of the hematuria evaluation. Researchers will measure how accurately the multiplex ELISA assay detects bladder cancer compared to current methods. The study includes monitoring for diagnostic performance over a year, with participants expected to complete the full hematuria evaluation during that time. The total duration of participation varies but centers on the one-year outcome assessment.

Age: 18Years - 90YearsAll Genders
8 locations
E

Actively Recruiting

Researchers are studying a combination therapy called DISP-10, which includes DV-10 an adenovirus and idecabtagene vicleucel ide-cel, a BCMA-directed CAR T cell therapy, in adults with advanced gastrointestinal cancers such as colorectal, gastric, esophageal, gastroesophageal junction adenocarcinoma, and biliary tract carcinoma. This Phase 1 trial aims to assess the safety and tolerability of increasing doses of DISP-10 and later evaluate its safety and effectiveness at the recommended dose. Participants will receive lymphodepleting chemotherapy with fludarabine and cyclophosphamide a few days before ide-cel treatment. The study has two parts Part 1 involves dose escalation to find the recommended dose for expansion RDE, while Part 2 focuses on treating patients at this RDE dose to evaluate safety and response. The therapy involves leukapheresis to collect blood cells for ide-cel production, with possible bridging therapy during manufacturing, followed by administration of DV-10, chemotherapy, and ide-cel. During the study, participants will be monitored closely for treatment-related side effects and responses for up to two years, including evaluating adverse events, dose limiting toxicities, overall response rate, disease control, and survival. Additional measures include pharmacokinetics of DV-10 and cellular kinetics of ide-cel. Some outcomes like overall survival will be followed for up to 15 years. Participants will have regular assessments and safety monitoring throughout the trial.

Age: 18Years +All GendersPhase 1
7 locations
P

Actively Recruiting

Researchers are conducting a Phase 1 study to evaluate BHV-1530 alone and in combination with cemiplimab in adults with advanced or metastatic solid tumors. This first-in-human, open-label trial aims to determine the safety, dosing, and potential benefits of BHV-1530 for patients whose cancer has progressed after standard treatments or who have no other available therapies. The study focuses on specific cancers including urothelial cancer, non-small cell lung cancer, and head and neck squamous cell carcinoma, especially those with certain genetic alterations. Participants will receive BHV-1530 as an intravenous infusion on Day 1 of each 21-day cycle, either alone or combined with cemiplimab given on the same schedule. The study includes dose escalation, expansion, and optimization phases to find the maximum tolerable dose and recommended dose range. Some groups may receive the drug alone, while others receive it combined with cemiplimab, with treatment continuing over multiple cycles as determined by the study protocol. During the trial, participants will have regular assessments to monitor safety and treatment effects, including tumor measurements according to RECIST 1.1 criteria and performance status evaluations. Researchers will collect tumor tissue samples, perform laboratory tests, and monitor drug levels in the blood. The main outcomes include determining optimal dosing, safety profile, and clinical benefit rates over an estimated 48 months. Participants health and response to treatment will be carefully followed throughout the study period.

Age: 18Years +All GendersPhase 1
17 locations
P

Actively Recruiting

Researchers are evaluating BMS-986500 as a treatment for people with advanced solid tumors, including advanced breast and ovarian cancer. This phase 1 study aims to assess BMS-986500 alone and in combination with other drugs in patients who have previously been treated with CDK46 inhibitors. The study focuses on understanding the safety and effects of BMS-986500 in these advanced cancer types. Participants will receive BMS-986500 either as a single treatment or combined with Palbociclib and Fulvestrant, depending on the study part. The study includes several parts, such as monotherapy dose escalation, combination dose escalation, pharmacodynamic sub-studies, and dose expansion phases. Treatments are given in specified doses on specified days, and the study monitors participants closely throughout these periods. During the study, participants will undergo regular assessments to track side effects, adverse events, and how the drug behaves in the body, including blood concentration over time. Researchers will monitor safety up to 28 days after the last dose and continue to observe some measures for up to approximately two years. The total duration of participation depends on the study part and treatment schedule.

Age: 18Years +All GendersPhase 1
21 locations
P

Actively Recruiting

Researchers are evaluating CPO301, an antibody drug conjugate, in adults with advanced or metastatic solid tumors who have progressed on prior treatments or are ineligible for standard therapy. This Phase 1 trial aims to assess the safety, tolerability, and optimal dosing of CPO301, as well as its pharmacokinetics, immunogenicity, and preliminary effectiveness, including its relationship to EGFR biomarker mutations. The study is sponsored by Conjupro Biotherapeutics, Inc. The trial has two parts. In Part A, patients receive escalating doses of CPO301 by intravenous injection every three weeks to identify the maximum tolerated dose or recommended phase 2 dose. In Part B, additional patients receive CPO301 at the dose determined safe and tolerable in Part A, focusing on those with non-small cell lung cancer with EGFR mutations and other tumor types. Treatment cycles last 21 days, and dose adjustments may be made based on safety assessments. Participants will provide informed consent, undergo screening to confirm eligibility, and attend study visits to receive CPO301 every three weeks until the study doctor decides to stop treatment. Researchers will monitor participants for disease progression every three months for up to two years. Safety, drug metabolism, immune response, and preliminary antitumor activity will be evaluated throughout the study, which is expected to last about one year for the primary outcomes.

Age: 18Years +All GendersPhase 1
14 locations

1-10 of 183

1